Vaccination Strategies Against Mycobacterium tuberculosis: BCG and Beyond

Ferluga, J.; Yasmin, Hadida; Bhakta, Sanjib; Kishore, Uday

doi:10.1007/978-3-030-67452-6_10

Cited by 2 publications

(1 citation statement)

References 137 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other hand, on celebrating the 100 years since BCG's first administration to humans, experts in the TB field already gave us an account of what specific and unspecific benefits and shortcomings have been discovered in this century of use [3,4]. Therefore, this work does not consider several aspects related to vaccine development, for which the reader may refer to other publications [1,2,4,5]. Also, topics such as innate trained immunity or the effect of BCG on cancer, which were comprehensively discussed by renowned experts in other publications in 2021 [4,[6][7][8], are outside the scope of this work.…”

Section: Introductionmentioning

confidence: 99%

After 100 Years of BCG Immunization against Tuberculosis, What Is New and Still Outstanding for This Vaccine?

Flores-Valdéz

2021

Vaccines

View full text Add to dashboard Cite

In 2021, most of the world was reasonably still concerned about the COVID-19 pandemic, how cases were up and down in different countries, how the vaccination campaigns were ongoing, and most people were familiar with the speed with which vaccines against SARS-Co-V2 were developed, analyzed, and started to be applied in an attempt to curb the pandemic. Because of this, it may have somehow passed relatively inadvertently for people outside of the field that the vaccine used to control tuberculosis (TB), Mycobacterium bovis Bacille Calmette-Guérin (BCG), was first applied to humans a century ago. Over these years, BCG has been the vaccine applied to most human beings in the world, despite its known lack of efficacy to fully prevent respiratory TB. Several strategies have been employed in the last 20 years to produce a novel vaccine that would replace, or boost, immunity and protection elicited by BCG. In this work, to avoid potential redundancies with recently published reviews, I only aim to present my current thoughts about some of the latest findings and outstanding questions that I consider worth investigating to help develop a replacement or modified BCG in order to successfully fight TB, based on BCG itself.

show abstract